黄玲 刘国辉

摘 要 目的：观察沙美特罗/氟替卡松吸入治疗老年中重度慢性阻塞性肺疾病的疗效。方法：选取老年中重度慢性阻塞性肺疾病患者140例，随机分为观察组和对照组各70例。对照组给予吸入沙丁胺醇气雾剂治疗，观察组给予吸入沙美特罗/氟替卡松治疗。比较两组患者治疗后的各项肺功能指标、动脉血气指标及不良反应发生情况。结果：观察组的FEV1、FVC及FEV1/FVC优于对照组；PaO2高于对照组、PaCO2低于对照组（P<0.05）。两组不良反应发生情况差异无统计学意义（P>0.05）。结论：老年中重度慢性阻塞性肺疾病给予吸入沙美特罗/氟替卡松治疗效果较好，可改善患者各项临床指标，且不良反应发生率较低。

关键词 沙美特罗/氟替卡松 吸入治疗 中重度慢性阻塞性肺疾病 老年患者

中图分类号：R974.3； R563 文献标志码：A 文章编号：1006-1533（2021）23-0043-03

Salmeterol/fluticasone inhalation in the treatment of moderate to severe chronic obstructive pulmonary disease in the elderly

HUANG Ling， LIU Guohui

（Department of Pulmonary， the Third People’s Hospital of Shenzhen， Shenzhen 518000， China）

ABSTRACT Objective： To observe and study the clinical effects of salmeterol/fluticasone inhalation in the treatment of moderate to severe chronic obstructive pulmonary disease （COPD） in the elderly. Methods： One hundred and forty elderly patients with moderate to severe COPD were selected and randomly divided into an observation group and a control group with 70 cases each. The control group was treated with inhaled salbutamol aerosol， while the observation group with inhaled salmeterol/fluticasone. The pulmonary function indexes， arterial blood gas indexes and the incidence adverse reactions in the two groups were observed and analyzed after treatment. Results： The FEV1 and FVC levels and FEV1/FVC value were significantly better， the PaO2 was significantly higher and the PaCO2 was significantly lower in the observation group than the control group （P<0.05）. There were no significant differences in the incidence of adverse reactions between the two groups （P>0.05）. Conclusion： Inhaling salmeterol/fluticasone have a significant effect for elderly patients with moderate to severe COPD， can significantly improve the clinical indicators of the patients and reduce the incidence of adverse reactions.

KEY WORDS salmeterol/fluticasone； inhalation therapy； moderate to severe chronic obstructive pulmonary disease； elderly patients

慢性阻塞性肺疾病（chronic obstructive pulmonary diseases， COPD）是一種具有高死亡率和致残率的顽固性疾病，主要特征为患者出现持续性气流受限症状，如果得不到及时治疗，病情可能会发展恶化至肺源性心脏病或者呼吸衰竭，严重影响患者的生命健康安全[1]。目前临床公认治疗COPD的方式主要包括抗胆碱能药物及b2-受体激动剂等。沙丁胺醇气雾剂是临床应用较广的一种b2-受体激动剂，可有效缓解COPD患者临床症状[2]。有研究表明[3]，长效支气管舒张剂可减轻患者症状，而吸入性糖皮质激素可有效作用于患者COPD急性加重期。沙美特罗/氟替卡松作为一种吸入长效b-受体激动剂/糖皮质激素，已经在临床上显示出一定的抗炎作用[4]。……